For investors

Biotts is the first biotechnology company in Central Europe to create proprietary preparations and drug formulas based on extracts of natural origin and proprietary carriers of active substances that increase their bioavailability. Patented proprietary carriers of active substances can also be used as a transport system for commonly used oncological, anti-inflammatory and analgesic drugs, increasing their targeted effects by up to 10 times, reducing the drug dose by 10 times and radically minimising the side effects of therapy.

The market

For several years now, the biotechnology market has been steadily showing a high growth rate. Total revenue reached its historically highest level of $139.4 billion in 2016. Expenditure on research and development increased by 12%, to $45.7 billion. Employment in biotechnology companies in the US and Europe increased to over 200,000 people, 14% more than a year before.


Revenues of the biotech sector companies since 2000:

Source: Report “Biotechnology Report Beyond Borders” by EY


Revenues of industry leaders (companies generating at least 500 million USD in revenues) increased by 8% to 122.4 billion USD in 2016, which represents 88% of the revenues of the entire sector. Since 2011, the amount of revenues generated by commercial leaders has doubled from the level of 61 billion USD. At the same time, the number of companies generating the highest revenues in the US and Europe increased from 23 to 27. 2016 was also the sixth consecutive year when the total expenditure on R&D increased.

BIOTTS product market

The market for transdermal drug transport systems

TTS-X
According to the MARKETSANDMARKETS report “Transdermal Second Delivery System Market – Global Forecast to 2022”, the global market for transdermal drug delivery systems (TDDS) in 2017 amounted to nearly $35.72 billion. By 2024, the TDDS market will be worth $81.46 billion. The average market growth is estimated at a record level of 12.5% per year.

Local anesthetics for epidermal anesthetics

TTS-A
The global market for anesthetic drugs in 2017 was worth $8,335 million. It is predicted that by 2022 the market will reach $9,240 million.
In Europe, the value of the anesthetics market is estimated at over €2.5 billion.
Main users of local anesthetics are beauty parlours, private clinics, and doctor’s surgeries.

Ulcers and difficult-to-heal wounds

TTS-U
Ulcers and difficult-to-heal wounds occur in about 1% of the population in Poland, a group comprising more than 390,000 people.
Chronic wounds occur in almost 15% of the elderly population (65+).
The problem of difficult-healing wounds affects more than 25 million people around the world, and this number will grow further due to an increasing prevalence of lifestyle diseases such as diabetes, obesity, and atherosclerosis. Difficult-to-heal wounds are twice as common in women as in men.

About 50-70% of all ulcers, if treated properly, heal within 4–6 months, while 20% do not heal for the next 24 months, and 8% for the next 5 years. After the age of 60, the frequency of such wounds is 0.6-3.0%, regardless of their cause, and in the age group over 80, it is over 5%.
The value of the Polish market alone as regards treatment of chronic wounds is over 750 million PLN.
In the US, the treatment of lower limb ulcers costs $3 billion and consumes over 2 million working days a year.

Multi-systemic tick-borne infections

CRP-32
In 2016 there were 232,125 new cases of borreliosis in the European Union, including 21,000 new cases in Poland alone. The number of new infections as regards tick-borne diseases increases from 40% to 56% each year. According to the WHO experts, data on the incidence is underestimated by more than 30%, as many patients do not realise that they suffer from borreliosis. Tick-borne infections can cause diseases such as rheumatoid arthritis (RA), multiple sclerosis (MS), chronic fatigue syndrome (CFS), tick-borne encephalitis, and many more.

According to Healthcare (Basel) studies and scientific publications, 1 million people are estimated to be infected with borreliosis in the United States and 2.4 million in Europe in 2018 alone. Scientists estimate that by 2050, 55.7 million people (12% of the population) will be infected with borreliosis in the United States and 134.9 million people (17% of the population) in Europe. Most of these infections will, unfortunately, become chronic. The estimated cost of treating acute and chronic borreliosis in 2018 in the US will range from $4.8 billion to $9.6 billion, and in Europe from €10.1 billion to €20.1 billion. There are currently no drugs available on the market that can effectively remove intracellular pathogens from the human body and guarantee a full recovery from chronic infection. The cure rate for tick-borne diseases is currently only 25% and is closely linked to the time of diagnosis and the start of antibiotic treatment.

Oncology

Breast cancer

TTS-B
1 in 8 women in the world is diagnosed with breast cancer and every 29 seconds a new case of breast cancer is confirmed.

In 2012, 1,700,000 women worldwide developed breast cancer. In the same year, 500,000 women died of breast cancer.

Breast cancer is the most common type of cancer, accounting for as much as 21% of detected cases. In Poland, breast cancer is diagnosed in about 17,000 women every year, and over 6,000 women die of breast cancer in Poland annually.

In 2018, the global market for breast cancer medicines was worth $13.4 billion, and in 2021 it will reach $17.2 billion. According to the GlobeNewswire report, the market for oncological drugs for breast cancer by 2025 may even grow to the level of $28 billion.

Anorectal cancer

TTS-R
According to a WHO report, 8.8 million people worldwide died of cancer in 2015, representing about 1 in 6 of all deaths. In 2015, 774,000 people died of bowel cancer, of which rectal cancer accounted for 25%. According to Grand View Research, the value of medicines sold for intestinal cancer will be $8.9 billion in 2018, reaching $10.8 billion in 2022 and $12 billion in 2025.

Skin cancer

TTS-S
Skin cancer is the most common cancer detected among the young population aged 25-29, with the highest number of cases diagnosed in people over 60 years of age. Skin cancer is detected in 1/34 young men and 1/53 women. Every year, more than 3.8 million people with different skin cancers are diagnosed in the US, while melanoma is detected in more than 76,000 people a year. The annual cost of treating patients with melanoma in the US alone is $2.36 billion.

The Management Board

Paweł Biernat, PhD
CEO & Transdermal Systems Specialist

Co-founder and co-author of BIOTTS patents and therapeutic systems.

Jan Meler, PhD
Director of the Drug Development Department

Co-founder and co-author of BIOTTS patents and therapeutic systems.